21 Stocks on Jim Cramer’s Radar

Page 18 of 20

3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 68

Coming to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Cramer noted:

“We also get numbers from Vertex Pharma, including the first look at how its non-opioid painkiller is doing, that’s the one that’s not addictive. The numbers could be explosive here because the drug is revolutionary.”

Vertex Pharmaceuticals (NASDAQ:VRTX) focuses on developing and marketing treatments for cystic fibrosis. The company is also progressing a range of drug candidates in clinical testing for different diseases. According to its earnings report released on May 5, the company reported total revenue of $2.77 billion for the first quarter, which is a 3% increase year-over-year. The growth was mainly driven by ongoing demand for TRIKAFTA/KAFTRIO and initial sales from the U.S. launch of ALYFTREK.

As of March 31, Vertex Pharmaceuticals’ (NASDAQ:VRTX) cash, cash equivalents, and total marketable securities stood at $11.4 billion, slightly up from $11.2 billion reported at the end of December 2024.

Page 18 of 20